Motixafortide
Motixafortide is an FDA-approved CXCR4 antagonist. Haematopoietic stem cells are retained in the bone marrow niche largely through the CXCR4 receptor binding its ligand CXCL12. Motixafortide is a synthetic cyclic peptide that blocks CXCR4 with high affinity and a long receptor occupancy, releasing stem cells into peripheral blood where they can be collected by apheresis.
For research use only.
Key Facts
- CAS
- 664334-36-5
- Molecular Weight (MW)
- 2159.5 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
CXCR4 antagonist peptide approved, in combination with filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma.
Peptide Library's Motixafortide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Motixafortide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C97H144FN33O19S2 |
|---|---|
| Molecular weight | 2159.5 g/mol |
| CAS number | 664334-36-5 |
| PubChem CID | 91865076 |
| FDA UNII | DA9G065962 |
| ChEMBL | CHEMBL6067714 |
| DrugBank | DB14939 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Haematopoietic stem cells are retained in the bone marrow niche largely through the CXCR4 receptor binding its ligand CXCL12. Motixafortide is a synthetic cyclic peptide that blocks CXCR4 with high affinity and a long receptor occupancy, releasing stem cells into peripheral blood where they can be collected by apheresis.
Studies
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
- GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma
- Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- WBC Growth Factors: ASCO Guideline Update
Regulatory & research status
Motixafortide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Motixafortide: frequently asked questions
What is Motixafortide?
CXCR4 antagonist peptide approved, in combination with filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma.
How does Motixafortide work?
Haematopoietic stem cells are retained in the bone marrow niche largely through the CXCR4 receptor binding its ligand CXCL12. Motixafortide is a synthetic cyclic peptide that blocks CXCR4 with high affinity and a long receptor occupancy, releasing stem cells into peripheral blood where they can be collected by apheresis.
Is Motixafortide FDA approved?
Yes. Motixafortide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Motixafortide?
Compounds most often compared with Motixafortide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial — Nat Med, 2023External reference
- GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma — Future Oncol, 2019External reference
- Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial — Clin Cancer Res, 2021External reference
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial — Nat Med, 2020External reference
- WBC Growth Factors: ASCO Guideline Update — J Clin Oncol, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Motixafortide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Motixafortide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →